TLC BioSciences Reports Positive TLC590 Phase 3 Topline Results
TLC BioSciences says its pivotal Phase 3 trial of investigational TLC590 showed statistically significant reductions in pain and opioid use versus placebo and liposomal bupivacaine.
Story updates
10:07:14 AM UTC
SquawkNews
TLC BioSciences said its Phase 3 TLC590 trial in bunionectomy met the primary endpoint vs placebo (p=0.0024) and showed superiority to liposomal bupivacaine on pain and opioid use; benefits persisted to 168 hours. TLC plans NDA preparation.Material DetailsContext by AI AnalystThis is a late-stage c…
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- TLC BioSciences Corp. (TPEx: TLC-KY; ticker: 7924; “TLC”) today announced positive topline results from its pivotal Phase 3 trial of TLC590, an investigational extended-release formulation of ropivacaine, for the mana…